{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T22:05:11Z","timestamp":1779487511096,"version":"3.53.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.maturitas.2026.108898","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:59:46Z","timestamp":1772524786000},"page":"108898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Breast cancer risk in peri- and postmenopausal women with a history of hormonal contraceptive use: A narrative review"],"prefix":"10.1016","volume":"208","author":[{"given":"Dewonna","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fraker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneela","family":"Vegunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paru S.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.maturitas.2026.108898_bb0005","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.maturitas.2026.108898_bb0010","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"issue":"10439","key":"10.1016\/j.maturitas.2026.108898_bb0015","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(24)00747-5","article-title":"The lancet breast cancer commission","volume":"403","author":"Coles","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2026.108898_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072612","article-title":"Management of perimenopausal and menopausal symptoms","volume":"382","author":"Duralde","year":"2023","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.maturitas.2026.108898_bb0025","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.maturitas.2026.108898_bb0030","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2105\/AJPH.2016.303349","article-title":"Exogenous hormone use: oral contraceptives, postmenopausal hormone therapy, and health outcomes in the nurses\u2019 health study","volume":"106","author":"Bhupathiraju","year":"2016","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.maturitas.2026.108898_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2025.108750","article-title":"Effect of duration of hormonal contraceptive use on breast cancer risk: a systematic review and meta-analysis of cohort studies","volume":"202","author":"Sayon-Orea","year":"2025","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108898_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.43730","article-title":"Association of hormonal contraceptive use with adverse health outcomes: an umbrella review of meta-analyses of randomized clinical trials and cohort studies","volume":"5","author":"Brabaharan","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.maturitas.2026.108898_bb0045","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1158\/0008-5472.CAN-20-2476","article-title":"Time-dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers","volume":"81","author":"Karlsson","year":"2021","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.maturitas.2026.108898_bb0050","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.maturitas.2026.108898_bb0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women\u2019s health initiative randomized clinical trials","volume":"324","author":"Chlebowski","year":"2020","journal-title":"Jama"},{"issue":"9017","key":"10.1016\/j.maturitas.2026.108898_bb0060","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies","volume":"347","author":"C.G.o.H.F.i.B. Cancer","year":"1996","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.maturitas.2026.108898_bb0065","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1210\/endo.140.12.7179","article-title":"The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens","volume":"140","author":"Hall","year":"1999","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.maturitas.2026.108898_bb0070","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/1097-0142(19841101)54:9<1920::AID-CNCR2820540924>3.0.CO;2-F","article-title":"The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice","volume":"54","author":"McManus","year":"1984","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108898_bb0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/(SICI)1096-9896(199907)188:3<237::AID-PATH343>3.0.CO;2-8","article-title":"Oestrogen receptor expression in the normal and pre-cancerous breast","volume":"188","author":"Shoker","year":"1999","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108898_bb0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.33795","article-title":"Racial\/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: the multiethnic cohort study","volume":"150","author":"Sarink","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.maturitas.2026.108898_bb0085","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/DDDT.S336643","article-title":"The role of progesterone receptors in breast cancer","volume":"16","author":"Li","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"issue":"7320","key":"10.1016\/j.maturitas.2026.108898_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108898_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.56142","article-title":"Incidence rate trends of breast cancer overall and by molecular subtype by race and ethnicity and age","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.maturitas.2026.108898_bb0100","series-title":"Breast Cancer Facts & Figures 2024\u20132025","author":"American Cancer Society","year":"2024"},{"issue":"7","key":"10.1016\/j.maturitas.2026.108898_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.19236","article-title":"Exogenous hormones, tumor intrinsic subtypes, and breast cancer","volume":"8","author":"Le Cornet","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"7621","key":"10.1016\/j.maturitas.2026.108898_bb0110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bmj.39289.649410.55","article-title":"Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study","volume":"335","author":"Hannaford","year":"2007","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.maturitas.2026.108898_bb0115","doi-asserted-by":"crossref","first-page":"821.e1","DOI":"10.1016\/j.ajog.2021.12.022","article-title":"Oral contraceptive use by formulation and breast cancer risk by subtype in the nurses\u2019 health study II: a prospective cohort study","volume":"226","author":"Burchardt","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.maturitas.2026.108898_bb0120","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2105\/AJPH.2016.303349","article-title":"Exogenous hormone use: oral contraceptives, postmenopausal hormone therapy, and health outcomes in the nurses\u2019 health study","volume":"106","author":"Bhupathiraju","year":"2016","journal-title":"Am. J. Public Health"},{"issue":"10","key":"10.1016\/j.maturitas.2026.108898_bb0125","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus guidelines on genetic` testing for hereditary breast cancer from the American Society of Breast Surgeons","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann. Surg. Oncol."},{"issue":"18","key":"10.1016\/j.maturitas.2026.108898_bb0130","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.maturitas.2026.108898_bb0135","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"25","key":"10.1016\/j.maturitas.2026.108898_bb0140","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group","volume":"25","author":"Brohet","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108898_bb0145","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/JCO.24.00176","article-title":"Hormonal contraception and breast cancer risk for carriers of germline mutations in BRCA1 and BRCA2","volume":"43","author":"Phillips","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108898_bb0150","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-013-2823-4","article-title":"Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers","volume":"143","author":"Kotsopoulos","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"23","key":"10.1016\/j.maturitas.2026.108898_bb0155","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"94","author":"Narod","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108898_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky023","article-title":"Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study","volume":"2","author":"Schrijver","year":"2018","journal-title":"JNCI Cancer Spectr."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108898_bb0165","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jnci\/djac004","article-title":"Oral contraceptive use in BRCA1 and BRCA2 mutation carriers: absolute cancer risks and benefits","volume":"114","author":"Schrijver","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108898_bb0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/GME.0000000000002136","article-title":"Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients","volume":"30","author":"Pederson","year":"2023","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108898_bb0175","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.clbc.2017.10.016","article-title":"Combined hormonal contraceptive use and risk of breast cancer in a population of women with a family history","volume":"18","author":"Grandi","year":"2018","journal-title":"Clin. Breast Cancer"},{"issue":"4","key":"10.1016\/j.maturitas.2026.108898_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7304a1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2024","volume":"73","author":"Nguyen","year":"2024","journal-title":"MMWR Recomm. Rep."},{"issue":"36","key":"10.1016\/j.maturitas.2026.108898_bb0185","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015719","article-title":"Effect of age at first use of oral contraceptives on breast cancer risk: an updated meta-analysis","volume":"98","author":"Ji","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.maturitas.2026.108898_bb0190","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1093\/carcin\/bgu144","article-title":"Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer","volume":"35","author":"Singer","year":"2014","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108898_bb0195","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10911-021-09497-0","article-title":"Estetrol and mammary gland: friends or foes?","volume":"26","author":"Gallez","year":"2021","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108898_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004188","article-title":"Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis","volume":"20","author":"Fitzpatrick","year":"2023","journal-title":"PLoS Med."},{"issue":"11","key":"10.1016\/j.maturitas.2026.108898_bb0205","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/ijc.31266","article-title":"Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: the Norwegian Women and Cancer Study","volume":"142","author":"Busund","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"7320","key":"10.1016\/j.maturitas.2026.108898_bb0210","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.maturitas.2026.108898_bb0215","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114314","article-title":"Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation","volume":"13","author":"Shamseddin","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.maturitas.2026.108898_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2023.106440","article-title":"Progestins and breast cancer hallmarks: the role of the ERK1\/2 and JNK pathways in estrogen receptor positive breast cancer cells","volume":"237","author":"Louw-du Toit","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.maturitas.2026.108898_bb0225","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jsbmb.2014.05.007","article-title":"A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A)","volume":"143","author":"Africander","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"8","key":"10.1016\/j.maturitas.2026.108898_bb0230","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1158\/0008-5472.CAN-11-4064","article-title":"Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age","volume":"72","author":"Li","year":"2012","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108898_bb0235","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00404-023-07265-5","article-title":"Depot medroxyprogesterone acetate and breast cancer: a systematic review","volume":"309","author":"Z\u00fcrcher","year":"2024","journal-title":"Arch. Gynecol. Obstet."},{"issue":"5","key":"10.1016\/j.maturitas.2026.108898_bb0240","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.contraception.2003.12.015","article-title":"Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer","volume":"69","author":"Strom","year":"2004","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.maturitas.2026.108898_bb0245","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jnci\/djae282","article-title":"Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers","volume":"117","author":"Tuesley","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2026.108898_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.781066","article-title":"Breast cancer risk with progestin subdermal implants: a challenge in patients counseling","volume":"12","author":"Mohammed","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:26:18Z","timestamp":1779485178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"alternative-id":["S0378512226000757"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108898","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer risk in peri- and postmenopausal women with a history of hormonal contraceptive use: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108898"}}